C-NGJ7Itasca Therapeutics
precision oncology, RAS/MAPK pathway
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NGJ7
C-NGJ7C-NGJ7precision oncology, RAS/MAPK pathway
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The main purpose of the study is to assess whether the study drug, ERAS-4001, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain KRAS mutations. ERAS-4001 will be given alone or in combination with other treatments.
The main purpose of the study is to assess whether the study drug, ERAS-0015, is safe and tolerable when administered to patients with advanced or metastatic solid tumors with certain RAS mutations. ERAS-0015 will be given alone or in combination with other treatments.
Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2. Stage 2: To compare progression free survival (PFS) and overall survival (OS) for patients with NRAS-mutant (NRASm) melanoma who are randomized to receive the combination of naporafenib + trametinib to that of patients who are randomized to physician's choice of therapy (dacarbazine, temozolomide, or trametinib monotherapy).
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors * To evaluate the safety and tolerability of naporafenib administered with trametinib in patients with RAS Q61X solid tumors * To characterize the pharmacokinetic (PK) profile of naporafenib and trametinib when administered to patients with RAS Q61X solid tumors
* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the preliminary efficacy of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with hematologic malignancies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
* To evaluate the safety and tolerability of escalating doses of ERAS-007 in combination with other cancer therapies in study participants with advanced GI malignancies. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 and other cancer therapies when administered in combination.
* To evaluate the safety and tolerability of escalating doses of ERAS-007 or ERAS-601 in combination with other cancer therapies in study participants with advanced non-small cell lung cancer (NSCLC). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 or ERAS-601 administered in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-007 or ERAS-601 in combination with other cancer therapies. * To evaluate the PK profiles of ERAS-007 or ERAS-601 and other cancer therapies when administered in combination.
* To evaluate the safety and tolerability of ERAS-007 monotherapy administered once weekly (QW) and twice daily-once weekly (BID-QW). * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 monotherapy administered BID-QW. * To characterize the pharmacokinetic (PK) profile of ERAS-007 monotherapy. * To determine the optimal dose and schedule of ERAS-007 monotherapy. * To evaluate antitumor activity of ERAS-007 in various solid tumors. * To evaluate the safety and tolerability of ERAS-007 (BID-QW) and ERAS-601 (twice daily for three weeks on and 1 week off (BID 3/1)) when administered in combination. * To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-007 administered in combination with ERAS-601. * To characterize the pharmacokinetic (PK) profile of ERAS-007 and ERAS-601 when administered in combination. * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors * To evaluate antitumor activity of ERAS-007 and ERAS-601 when administered in combination in various solid tumors
* To evaluate the safety and tolerability of escalating doses of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies in study participants with advanced or metastatic solid tumors. * To determine the Maximum Tolerated Dose (MTD) and/or recommended dose (RD) of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To characterize the pharmacokinetic (PK) profile of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies. * To evaluate the antitumor activity of ERAS-601 when administered as a monotherapy and in combination with other cancer therapies.
%PDF-1.4 %���� 668 0 obj > endobj xref 668 114 0000000016 00000 n 0000003078 00000 n 0000003215 00000 n 0000003440 00000 n 0000003525 00000 n 0000004681 00000 n 0000005211 00000 n 0000005774 00000 n 0000006281 00000 n 0000006327 00000 n 0000006375 00000 n 0000006425 00000 n 0000006475 00000 n 0000006525 00000 n 0000006574 00000 n 0000006624 00000 n 0000006674 00000 n 0000006724 00000 n 0000006774 00000 n 0000006824 00000 n 0000010505 00000 n 0000010730 00000 n 0000014074 00000 n 0000014452 00000 n 0000017567 00000 n 0000017951 00000 n 0000021063 00000 n 0000023556 00000 n 0000026490 00000 n 00
%PDF-1.7 %���� 1 0 obj >/Metadata 947 0 R/ViewerPreferences 948 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/Pattern >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 2592 1728] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}[����#� *�ĉ%'ܥ¥n3E�Z�ز�-���Z硚]��M��l��0�j���U,����j��b�C�L$2? �E�j��zE�憔:=���?h>:���'��'u�09 �4V�t�L ��l�x0�s*�I�̛�S����BT�v;�'��f��^��v��x�M�u��ؙm��?+�cu?�Гd��g�\nn�+��jr��$�9~�&�[��]AO��� �;�5~�J��d}�xfH�墑ѨJ����&��kxf�B�K�B�ߠ���yq���%�j�#��·% �L_eY.� ��_�{�:߿���\�?���3>2{i},>�e�BUߘۯ�Ot = ~Q�� �����%�
Science - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Competitive Benefits Open Positions Stay in Touch 858.465.6511 [email protected] science TARG
ERAS-4001 / Erasca, Medshine Discovery ERAS-4001 / Erasca, Medshine Discovery - LARVOL DELTA Home Next Prev 1 to 18 Of 18 Go to page 1 May 12, 2026 Research and Development (R&D) Highlights (The Manila Times) - "In April 2026, Erasca announced that dose escalation of ERAS-0015 in combination with anti-EGFR monoclonal antibody panitumumab was initiated in the first quarter of 2026 and that the monotherapy expansion cohorts for ERAS-0015 were initiated in the second quarter of 2026. Both of these milestones were completed ahead of the original second half of 2026 guidance...AURORAS-1: Phase 1 tr … eNewswire) - "Erasca...announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ERAS-4001, a potential first-in-class and best-in-class pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant (KRASm) solid tumors....'We look forward to continued efficient execution across our RAS-targeting programs and anticipate disclosing initial monotherapy data in 2026'....The BOREALIS-1 Phase 1 trial will … obeNewswire) - "ERAS-0015 – Potential Best-in-Class Pan-RAS Molecular Glue: IND application cleared by the FDA; Initial AURORAS-1 Phase 1 monotherapy data in RASm solid tumors expected in 2026...ERAS-4001: Potential First-in-Class Pan-KRAS inhibitor: IND application submitted to the FDA; Initial BOREALIS-1 Phase 1 monotherapy data in KRASm solid tumors expected in 2026." IND • New P1 trial • Oncology • Solid Tumor Print Email More sharing Reddit StumbleUpon Delicious May 13,
Pipeline - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Competitive Benefits Open Positions Stay in Touch 858.465.6511 [email protected] pipeline De
Science - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Competitive Benefits Open Positions Stay in Touch 858.465.6511 [email protected] science TARG
Erasca details RAS pipeline progress and milestones | ERAS 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil … es; the sufficiency of its cash, cash equivalents, and marketable securities to fund operations; the Company may use its capital resources sooner than it expects; and other risks described in the Company’s prior filings with the SEC, including under the heading “Risk Factors” in its annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking s
--> Erasca to Present at the Morgan Stanley Global Healthcare Conference --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
MPW GmbH - 2026 Company Profile - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and Startups Corp Dev and
Team - GCSG - Global Clinical Supplies Group Menu About Our Mission Team Become a volunteer Community Membership Join GCSG Member directory e-Teams Advanced Therapies Expanded Access Resource Regulatory Resources Resource Center Vendor Directory Country Regulations Database Discussion forum Events Global Pharma/Biotech Pass North America Europe Asia Pac All Upcoming Events Sponsor an Event Topic Proposal Careers Job board Post a job Search for: Login Join Explore GCSG Gather Events Attend one of our leading global clinical supplies conferences and webinars. Read More Collaborate Forum Get your … conference attendee name badges Coordinates the ordering, delivery to site and application of all conference attendee ribbons Attends the annual F2F M&M Functional Team meeting and regularly scheduled Conference Committee meetings as required Has a shared responsibility for supporting the organization’s financial sustainability Generally does not attend the conference planning meeting (F2F) Email Hope Foudoulakis Beren Therapeutics US Assistant Presentation Coordinator M … ng conferences (European Logistics Coordinator Only) Prepares venue summary and proposal for event locations in collaboration with the Contracts Manager for Logistics Officer to present to the GCSG Board (European Logistics Coordinator Only) Develop and maintain the regional conference Logistics budget Negotiate and set Logistics contracts in collaboration with Contracts Manager, i.e., hotel, food, audio visual, entertainment venue (European Logistics Coordinator Only) In col … ng conferences (European Logistics Coordinator Only) Prepares venue summary and proposal for event locations in collaboration with the Contracts Manager for Logistics Officer to present to the GCSG Board (European Logistics Coordinator Only) Develop and maintain the regional conference Logistics budget Negotiate and set Logistics contracts in collaboration with Contracts Manager, i.e., hotel, food, audio visual, entertainment venue (European Logistics Coordinator Only) In col … conference attendee name badges Coordinates the ordering, delivery to site and application of all conference attendee ribbons Attends the annual F2F M&M Functional Team meeting and regularly scheduled Conference Committee meetings as required Has a shared responsibility for supporting the organization’s financial sustainability Generally doe
Erasca, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Erasca, Inc. Public Company | 2018 | California, United States | 100-250 | NASDAQ: ERAS | www.erasca.com Public Company | 2018 | California, United States | 100-250 | NASDAQ: ERAS | www.erasca.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Digestive System Disorders Respiratory Diseases Small molecule drug Bispecific antibody Molecular glue Disea … ulatory developments in the United States and foreign countries; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on thes … LLER "CHASING MY CURE" BASED ON LIFE OF DR. DAVID FAJGENBAUM -Academy Award Winning Producer Wendy Finerman collaborates with Former Star Quarterback turned Pioneering Doctor and entrepreneur Jonathan E. Lim for inspirational Medical Drama- LOS ANGELES, April 17, 2025 /PRNewswire/ -- City Hill Arts, the film and media production and financing company founded by biotech entrepreneur Jonathan E. Lim, M.D., has optioned and immediately put into development Chasing My C … e diseases. Chasing My Cure will be written by Amy Snow and produced by Academy Award winning producer Wendy Finerman and Robin Jonas alongside Lim. The film will be executive produced by Steven P. Wegner and Lisa Zupan. "I am so thankful to be alive and to be able to share my story with the world, but I never could have dreamed that it would end this way," said Dr. Fajgenbaum. "Going through it, the experience felt pretty similar to a movie thriller—the same drop in your sto … sive list of credits includes Fairy Tale –A True Story which earned her a BAFTA Award for Best Children's Film, P.S. I Love You, Drumline, Stepmom, and Academy Award nominated The Devil Wears Prada. Collectively, all of her films have grossed over 1.6 billion dollars in international theatrical release and earned 160 award nominations. Her next f
%PDF-1.4 %���� 1 0 obj > endobj 8 0 obj > endobj 2 0 obj > endobj 3 0 obj > stream Jun11 PBSS-TABS_shared0310 Jun11 PBSS-TABS_shared0310 Adrienne Li endstream endobj 4 0 obj > endobj 5 0 obj > endobj 6 0 obj > endobj 7 0 obj > endobj 9 0 obj > /Font 50 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [51 0 R] /Contents 52 0 R /StructParents 0 /Tabs /S /Parent 2 0 R /BleedBox [0.0 7.9200063 612.0 799.92] /TrimBox [0.0 7.9200063 612.0 799.92] /CropBox [0.0 7.9200063 612.0 799.92] /Rotate 0 >> endobj 10 0 obj > /Font 60 0 R >> /MediaBox [0.0 7.9200063 612.0 799.92] /Annots [61 0 R] /Contents … q���x����v��v5�ގ>W mw'Ʊ���X��X����M��M1�[ :� )��,�OWf���� beш�mx�a�jc )���rFp1���s/ɽ"�9?��҅=���=�I�|�ٗ����qǍ�n���)�.�����',���c[ [?�堭�)G�nf3��2�T,@*F�c�J�t4p�9�vҧ� �n�. 17aTbi�h#�FD��% �Ã�-�q�����L4�Y4&"[�У�6@9�� қ����C ��� P �U�f��'ai��yVg���=�,� ��#�)%��hcjL��� T������_��tr�"�=� d�/���ϊn*�B+K����+|9���p��G ����>�%�����W���������O����aD��x��x?;��o] �� ��vt�����m[�r�ܿ��[v���}� Z=�q�ܠ��SO�n��gg�ws 3j� Z_�(��-O�� �j��zoDp�|Y$ ы��I!xv�
Erasca posts $183.4M Q1 loss on RAS pipeline spend | ERAS 8-K Filing --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & … illion in cash, cash equivalents, and marketable securities and expects this to fund operations into the second half of 2028. Total operating expenses rose to $187.9 million, driven by $150.0 million of in-process R&D expense to obtain worldwide rights to ERAS-0015, alongside $27.3 million in R&D and $10.6 million in G&A. Net loss widened to $183.4 million, or $(0.60) per share. Strategically, Erasca advanced ERAS-0015 and ERAS-4001, signed clinical trial collaborations with … sed about $258.8M in gross proceeds. Management indicates this liquidity should fund operations into the second half of 2028, which is important for a clinical-stage company without product revenue. Pipeline progress included positive preliminary ERAS-0015 monotherapy data, new clinical trial collaborations with Merck and Tango Therapeutics , and issuance of a U.S. composition of matter patent for pan-KRAS inhibitor ERAS-4001 through June 2043. Upcoming readouts for AURORAS-1 … quivalents, and marketable securities $408.5M As of March 31, 2026; expected to fund operations into H2 2028 Cash, cash equivalents, and marketable securities $341.8M As of December 31, 2025; prior period cash level Total operating expenses $187.9M Quarter ended March 31, 2026 In-process research and development expense $150.0M Q1 2026 charge to expand ERAS-0015 license territory to worldwide Research and development expenses $27.3M Quarter ended March 31, 2026 General and ad … uidance Erasca expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Add on Google Not now Understanding 8-K Material Events → Available on EDGAR 05/11/2026 - 04:06 PM
Namesake of Shoemaker High School, General Robert Shoemaker, dies at 93 Watch Now Menu Local National Weather Sports Shop Scripps Watch Now Watch Now Close × Live Watch Alerts Search site Go 25 News KXXV In Your Neighborhood Bell County Bosque County Burnet County Coryell County Falls County Freestone County Hill County Lampasas County Limestone County McLennan County Mills County San Saba County Williamson County News Local News Texas News National News Crime & Court Specials Legacy #25Cares Weather Daily Forecast Hourly Forecast Alerts 25 News Storm Tracker More Than A Forecast Wea … XV Meet the Team Contact KXXV TV Listings Advertise with KXXV KXXV Job Postings Submit a Tip SPECIAL FEATURES Wellness Experts Good Morning Texas Don't Waste Your Money Give a Child a Book 15ABC KRHD KRHD Local News Brazos County Burleson County Grimes County Leon County Madison County Milam County Robertson County Washington County About 15ABC KRHD Meet the KRHD Team Contact KRHD TV Listings KRHD Job Postings KRHD Social Media Facebook Instagram Twitter KRHD Give a Chil … d engineering academy within the high school Shoemaker endowed the Wolf-Warrior Scholarship in 2013 to enable the students to pursue a four-year bachelor's degree through Central Texas College and Texas A&M University - Central Texas. Shoemaker's service extends to the community, where he has tirelessly devoted himself to improving the quality of life for local residents, serving eight years as the elected Bell County Commissioner and fostering a close relationship betwee … honor and integrity earning numerous awards including the Distinguished Service Award, the Bronze Star and the Silver Star. He served in multiple battles, including the Korean War, the Vietnam War and during the Cold War. In addition to his outstanding military service, General Shoemaker served the Ft. Hood community and all of Bell County. He was a former Bell County Commissioner, an avid volunteer for the Heart of Texas Boy Scouts and for Central Texas United Way. For his c … munity, I was proud to have awarded him the Congressional Veterans Commendation award. I am honored to have had the opportunity to get to know General Shoemaker and call him my friend. My family, my staff, and I send our prayers to his family and loved ones at this time. He was a giant in our community, and he will be sorely missed. God Bless him
Professor Robert Shoemaker | Gresham College Skip to main content Fulltext search Main Nav-2 items What's on Watch now Login Donate Fulltext search Suggested searches: Astronomy Religion Chris Whitty Maths Barnard's Inn Hall For the Love of Learning since 1597 Gresham College provides outstanding educational talks and videos for the public free of charge. There are over 3,500 videos available on our website. Your support will help us to encourage people's love of learning for many years to come. Donate Today Main navigation What's on Lecture Series' 2025-26 Venues Acc
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Speaker Series: Building Companies from Exceptional Science, Robert Nelsen - UCSF Events Calendar --> University of California San Francisco Give to UCSF Search Search Log in Sign up UCSF Events Calendar Past Events Speaker Series: Building Companies from Exceptional Science, Robert Nelsen Clear message Speaker Series: Building Companies from Exceptional Science, Robert Nelsen By Entrepreneurship Center Monday, May 1, 2017 5:30pm to 7:30pm PDT I'm Interested Register Share Speaker Series: Building Companies from Exceptional Science, Robert Nelsen Share Speaker Series: Building Companies fr … endment. Follow Us: Facebook Twitter YouTube Instagram --> General Login Submit an event All events Disability Resources All groups All places FAQs Contact Topic Awards & Celebrations Advocacy & Fundraising Fitness & Wellbeing Fun & Recreation Professional Development Research & Academia Town Halls Audience Alumni Faculty Local Community Patients Postdocs Staff Students UCSF welcomes all participants to our events. If you require a reasonable accommodation to participa
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat – 1stOncology™: Cancer Intelligence Service 1stOncology™: Cancer Intelligence Service 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Skip to content 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider Continue your journey with 1stOncology by accessing our Free Leading Cancer Conference Whitepapers , signing up for our Free Weekly Newsletter and requesting a Free Demo to see how we can help you be 1st in Oncology! Access Free Confe
Erasca Plummets Despite... - Investor's Business Daily Facebook Log In Investor's Business Daily's Post Investor's Business Daily Verified account April 28 · Shared with Public Erasca Plummets Despite 'Phenomenal' Results In Pancreatic Cancer investors.com Biotech Hammered Despite 'Phenomenal' Data; Here's Why All reactions: 7 1 comment Like Comment Most relevant
Erasca's RAS Cancer Breakthroughs at ASCO2026 | Erasca, Inc. posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to L
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting – Erasca | Erasca, Inc. LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree
ERAS – Erasca, Inc. 13F Top Holders Q1 2022 vs. Q4 2023 Erasca, Inc. Q1 2022 vs. Q4 2023 13F Holders Period Q1 2022 Q4 2023 Num holders 84 125 Total reported value, excl. options $627 M $152 M Total shares, excl. options 72,853,395 71,324,209 Compare Q4 2023 to 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q3 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1 2021 Q4 2021 Q3 Manager Q1 2022 Shares Q4 2023 Shares Diff Chg % All Managers A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 Latest Filings Privacy Policy
CATO LYSSAND HOLDING AS - 2026 Company Profile - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and Startup
ARDD GmbH - 2026 Company Profile - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corporates and Startups Corp Dev and
Erasca, Tango sign ERAS-0015 cancer combo trial | ERAS Stock News --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks Oil & Ga … es; the sufficiency of our cash, cash equivalents, and marketable securities to fund operations; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking st
Erasca and Tango Therapeutics Enter into Clinical --> Accessibility: Skip TopNav Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat March 05, 2026 07:01 ET | Source: Erasca, Inc. Erasca, Inc. ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015 at no cost SAN DIEGO, March 05, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discove … es; the sufficiency of our cash, cash equivalents, and marketable securities to fund operations; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2024, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking st
San Diego-Based Erasca Raises $42 Million To Target Biological Drivers Of Cancer VC PE M&A Asset Management Law Firms Profiles Contact × Search Pulse 2.0 San Diego-Based Erasca Raises $42 Million To Target Biological Drivers Of Cancer By Amit Chowdhry • Dec 19, 2018 San Diego-Based Erasca Raises $42 Million To Target Biological Drivers Of Cancer Erasca, a San Diego, California-based company, has raised $42 million in Series A funding co-led by founding investors City Hill Ventures and Cormorant Asset Management. Additional institutional and individual investors also participated in
10-K 0001761918 false FY 3 One http://fasb.org/srt/2025#ChiefExecutiveOfficerMember http://fasb.org/us-gaap/2025#AccountingStandardsUpdate202309Member http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2025#PrepaidExpenseAndOtherAssetsCurrent One http://fasb.org/srt/2025#ChiefExecutiveOfficerMember 0001761918 us-gaap:ShortTermInvestmentsMember us-gaap:USTreasurySecuritiesMember us-gaap:FairValueMeasurementsRecurringMember 2025-12-31 0001761918 eras:LaboratorySpaceMember eras:AmendmentToTheSeptemberTwoThousandTwentyFourSubleaseMember 2025-07-31 0001761918 u … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … clinical trial for ERAS-0015 is called AURORAS-1. The investigational new drug application (IND) for AURORAS-1 was cleared by the US Food and Drug Administration (FDA) in May 2025. ERAS-0015, which we license from Guangzhou Joyo Pharmatech Co., Ltd. (Joyo), is also being evaluated in the JYP0015M101 clinical trial in China, which is assessing ERAS-0015 in adult patients with advanced solid tumors harboring specific RAS mutations. The JYP0015M101 clinical trial is sponsored b … e early development of MEKINIST, and supported the successful biologics license application for IMFINZI in bladder cancer. 6   Dr. David Chacko, our Chief Financial Officer and Chief Business Officer, joined us from Versant Ventures, where he was a Principal with both investing and operating responsibilities. He helped lead investment opportunities across multiple therapeutic areas and advanced several Versant portfolio companies operationally through company formation, … Amsterdam and obtained his Ph.D. from Leiden University. After a post-doctoral fellowship, he became an assistant professor at Harvard University. In 1992, he joined the Netherlands Cancer Institute, where he continues to work at present. • Dr. Stephen Blacklow is a world expert in SHP2 who helped pioneer development of the first SHP2 inhi
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Erasca (ERAS) Form 144: Proposed Sale of 8,333 Shares on 09/15/2025 | ERAS SEC Filing - Form 144 --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes A
Erasca™ Launches with $42 Million Series A Financing to Support Bold Mission of Erasing Cancer - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Comp
ERAS-0015 - Page 1 | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 landscape PFA re-energizes afib market China CAR T A … Comments Erasca Inc. priced an upsized public offering to raise $225 million to fund development of its therapies for patients with RAS/MAPK pathway-driven cancers. Read More Cancer Erasca’s pan-KRAS inhibitor ERAS-4001 gains IND clearance June 3, 2025 No Comments Erasca Inc. has obtained IND clearance by the FDA for ERAS-4001, an oral selective pan-KRAS inhibitor, for the treatment of patients with KRAS-mutant solid tumors. Read More Erasca buys-in assets from two China biot
Erasca, Inc. (NASDAQ: ERAS) Securities Fraud Class Action | Kessler Topaz Skip to Main Content About › Overview Pro Bono Diversity & Inclusion Data Security Testimonials FAQ People › Practice Areas › Securities Fraud Corporate Governance & M+A Global Shareholder Litigation Direct & Opt-Out Antitrust Banking & Financial Services Healthcare Impact & Consumer Protection Data Privacy & Cyber Security Whistleblower Arbitration SecuritiesTracker™ Cases › Investigations New Cases Current Cases Recent Settlements Landmark Results News › News Insights Newsletters Awar … Tracker Site Erasca, Inc. (NASDAQ: ERAS) Securities Fraud Class Action Overview Submit your Information Company Erasca, Inc. Court United States District Court for the Southern District of California Case Number 3:26-cv-03481 Judge Honorable Anthony J. Battaglia Class Period January 14, 2025 through April 26, 2026 Security Type Common Stock Lead Plaintiff Deadline: August 10, 2026 Days Left to Lead Plaintiff Deadline: 43 The Erasca, Inc. class action lawsuit was filed on beha … n January 14, 2025 through April 26, 2026. Click Here to Print PDF of this Form SUBMIT YOUR INFORMATION * Denotes required field Country Select Country United States Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegov … u to file a lead plaintiff motion in this matter. READ MORE Any information you submit will be maintained as confidential. If Kessler Topaz, in its sole discretion, believes that you might be an appropriate lead plaintiff candidate, Kessler Topaz will contact you to discuss the matter and whether to establish an attorney client relationship. By submitting this form, you are authorizing us to contact you regarding this case and/or future cases. I agree to the KTMC disclaimer Y … to the KTMC disclaimer Yes I would like to receive new case alerts by email Yes Submit Your Information Disclaimer | Privacy Policy | SecuritiesTracker Log In KESSLER TOPAZ MELTZER & CHECK, LLP 2026 ALL RIGHTS RESERVED
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA® (Pembrolizumab) – Erasca | Rachel Cervantes LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject
Erasca, Inc. | Kirby McInerney LLP Javascript must be enabled for the correct page display Skip to Content Team Practices Cases Investigations Institutional Monitoring Search Team Practices Cases Investigations Institutional Monitoring Firm Overview Locations News Careers Contact Us Client Portal LOGIN Client Portal Subscribe to Our Newsletter Sign-up to receive the latest information from our firm SUBSCRIBE Subscribe Team Practices Cases Investigations Institutional Monitoring Firm Overview Locations News Careers Contact Us Client Portal LOGIN Client Portal Subscribe to Our Newsletter Sign-up … rview FAQs PDF Case Overview 45 Days Left to Seek Lead Plaintiff Lead Plaintiff Deadline: Lead Plaintiff Deadline: 08/10/2026 Status: Status: Investigating Company Name: Company Name: Erasca, Inc. Court: Court: Southern District of California Case Number: Case Number: 3:26cv03481 Class Period: Class Period: 01/14/2025 - 04/26/2026 Ticker: Ticker: ERAS Related Attorneys: Lead Attorneys: Thomas W. Elrod Related Practices: Related Practices: Securities The law firm of Kirby McIn … tment, you can contact Kirby McInerney via email at [email protected] or submit a contact form via the firm’s website. Critically, the decision to seek lead plaintiff appointment is time sensitive. Class members have sixty (60) days after a securities fraud class action lawsuit is filed to request the court for appointment as lead plaintiff. Q. What are the benefits and responsibilities of serving as lead plaintiff in a securities class action? A. If you have inc … court will sometimes compensate the lead plaintiff with an additional monetary award for their time and efforts in overseeing the case. Q. How do I know if I am eligible to participate in a securities class action? A. Any person who purchased the security at issue during the class period is eligible to participate. The attorneys at Kirby McInerney can quickly investigate the facts and advise you on your potential claim, as a lead plaintiff or a class member. Your rights are … se? A. You can contact Kirby McInerney via email at [email protected] or submit a contact form via the Firm’s website . * These "Frequently Asked Questions" are provided by Kirby McInerney LLP for educational and informational purposes only and is not intended and should not be construed as legal advice. Contact Us About This Case Case Sig
Erasca Unveils Its First Strategy to Erase Cancer, Accelerated by Expansion of Precision Oncology Pipeline and Dosing of First Patient – Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Reso
Erasca, Inc. Class Action Lawsuit - ERAS Jump to Content The Firm The Right Choice Prominent Cases & Precedent-Setting Decisions Judicial Commendations Clients Pro Bono & Community Service Community Sustainability Services Litigation Services Securities Fraud Delaware Practice Consumer Fraud and Privacy Shareholder Derivative Corporate Takeover Antitrust ERISA Investor Services Portfolio Monitoring Program ® Attorneys Cases Securities Cases Consumer Cases Settled Cases Notable Cases News Featured News Awards & Recognition Videos Contact Offices Contact Us Recruiting Search Search P … the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Submit Your Information First Name * Last Name * Email * Phone * City State/Province ZIP/Postal Code Country * Estimated Losses * Valid monetary value, for example, $1000.00 Are you a current or former employee of the company? * Yes, current employee Yes, former employee No, never an employee Would you like to receive future case and securities updates from Robbins Geller via email? * Yes No By cl
XML 57 R10.htm IDEA: XBRL DOCUMENT v3.24.1 Organization and Basis of Presentation 12 Months Ended Dec. 31, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract]   Organization and Basis of Presentation Note 1. Organization and basis of presentation   Organization and nature of operations   Erasca, Inc. (Erasca or the Company) is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for RAS/MAPK pathway-driven cancers. The Company has assembled a wholly-owned or controlled RAS/MAPK p … Company expects to use its cash, cash equivalents, and marketable securities to fund research and development, working capital, and other general corporate purposes. The Company does not expect to generate any revenues from product sales unless and until the Company successfully completes development and obtains regulatory approval for any of its product candidates, which will not be for at least the next several years, if ever. Accordingly, until such time as the Company can … duce or terminate its research and development programs or other operations, or grant rights to develop and market product candidates that the Company would otherwise prefer to develop and market itself. The Company believes its cash, cash equivalents, and marketable securities as of December 31, 2023 will be sufficient for the Company to fund operations for at least one year from the issuance date of these consolidated financial statements. Underwritten offering   In De
ERAS-0015 / Erasca, Guangzhou JOYO Pharma ERAS-0015 / Erasca, Guangzhou JOYO Pharma - LARVOL DELTA Home Next Prev 1 to 25 Of 30 Go to page 1 2 June 27, 2026 AURORAS-1: A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - P1 | N=600 | Recruiting | Sponsor: Erasca, Inc. | N=200 ➔ 600 Enrollment change • First-in-human • Monotherapy • Oncology • Solid Tumor Print Email More sharing Reddit StumbleUpon Delicious May 11, 2026 Erasca Announces Clinical Trial Collaboration and Supply Agreement with Merck to Evaluate ERAS-0015 in Combination with KEYTRUDA (Pe … obeNewswire) - "ERAS-0015 – Potential Best-in-Class Pan-RAS Molecular Glue: IND application cleared by the FDA; Initial AURORAS-1 Phase 1 monotherapy data in RASm solid tumors expected in 2026...ERAS-4001: Potential First-in-Class Pan-KRAS inhibitor: IND application submitted to the FDA; Initial BOREALIS-1 Phase 1 monotherapy data in KRASm solid tumors expected in 2026." IND • New P1 trial • Oncology • Solid Tumor Print Email More sharing Reddit StumbleUpon Delicious May 13,
Robert Shoemaker (robshoe187) - Profile | Pinterest Skip to content Explore When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures. Log in Sign up User Avatar R Robert Shoemaker robshoe187 Follow Created Saved Wedding Vibes , kcomollo K robshoe187 R , 58 Pins · , 4y Gear Organization , 42 Pins · , 4y Bridal shower games , 10 Pins · , 4y Speaker design , 123 Pins · , 5y Chassis Design , 135 Pins · , 5y Cars , 12 Pins · , 5y Weight watchers meals dinner , 2 Pins · , 5y Rob’s Dream Home Inspiration
Obituary for Robert W. Shoemaker | Wagner Family Funerals Wagner Family Funerals Home Page Robert W. Shoemaker Obituary & Services Tribute Wall Send Gifts Plant a Tree Share Share a Memory Send Sympathy Gifts Plant a Tree Share a memory Coping with Grief We would like to offer our sincere support to anyone coping with grief. Enter your email below for our complimentary daily grief messages. Messages run for up to one year and you can stop at any time. Your email will not be used for any other purpose. Official Obituary of Robert W. Shoemaker May 6, 2015 Be the first to offer your condolences o
Robert Shoemaker | Vaccine West Coast Toggle navigation World Vaccine Congress West Coast 2023 27 - 30 November Santa Clara Convention Center, Santa Clara, CA home our story Event Photos World Vaccine Congress Europe World Vaccine Congress Washington LinkedIn Twitter Supporting Partners Sponsorship/Exhibition floor plan sponsors & exhibitors 2023 Start-Ups download prospectus Branding Opportunities Partnering Apply to Sponsor/Exhibit 2023 agenda 2023 Speakers Conference Download Agenda Poster Sessions Scientific Advisory Board networking Apply to Speak Exhibitor Resources Build & Break … ished: 02/Jan/24 12:15 GMT back to speakers Contact Our Story Conference Apply to Speak Sponsor Enquire Download Prospectus TICKETS Created by Terrapinn is proud to be a member of isla. Working together to build sustainable events good conduct policy anti-slavery policy anti-money laundering & financial crime policy diversity & inclusion policy sustainability policy sanctions policy © Terrapinn Holdings Ltd. MMXXIII privacy general t&c's con
Professor Robert Shoemaker | History, Philosophy and Digital Humanities | The University of Sheffield Skip to main content Search sheffield.ac.uk Close menu × School of History, Philosophy and Digital Humanities Library item label woz ere --> Undergraduate Undergraduate study History courses Philosophy courses Careers Student profiles Postgraduate Postgraduate study Careers PhD funding Student profiles Research Our research Archaeology research Digital Humanities Institute History research Philosophy research People People Digital Humanities staff History staff Philosophy staff Professio … an and Minority Ethnic (BAME) students Accommodation University residences Rent Apply for accommodation Visit Undergraduate open days Postgraduate visits International visits to your region Sheffield Live online events Subject taster sessions for Y12 and Y13 students Apply Undergraduate applications Postgraduate taught applications PhD applications Applying as an international student Visas and immigration International students Our international community How to apply V … management Rankings A world top-100 university Queen's Anniversary Prizes Nobel Prize winners Schools, departments and services Schools Faculties Professional services Studying at Sheffield Guide to Sheffield Courses Hospitality Conferences, events, visitor accommodation and weddings Cafes and bars School of History, Philosophy and Digital Humanities Menu Library item label woz ere --> Undergraduate Undergraduate study History courses Philosophy courses Careers Student profil … In January 2011 Hitchcock and I were awarded the Longman-History Today Trustees Award , presented to a person, persons or organisation that has made a major contribution to history, for our work on the Old Bailey and London Lives projects. Print Culture I then researched how knowledge about crime was created in eighteenth and nineteenth-century London. Through analysis of the literature of crime and by examining evidence of its reception in private correspondence and diaries,
We’re honored to... - SCCC Public Safety Training Academy Facebook Log In SCCC Public Safety Training Academy's Post SCCC Public Safety Training Academy April 21, 2025 · Shared with Public We’re honored to welcome Mr. Robert Shoemaker, CFPS, ARM – Senior Fire Protection Specialist – as our guest speaker for tonight’s Chief Officer Development class. Tonights lesson: Insurance Services Office (ISO). As part of our mission to eliminate “death by PowerPoint,” we bring in Subject Matter Experts (SMEs) to deliver dynamic, real-world insights on the critical responsibilities Chief Officers face
Erasca details RAS-focused oncology pipeline in 10-K | ERAS Annual Report (10-K) --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto … eding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ NO ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” … clinical trial for ERAS-0015 is called AURORAS-1. The investigational new drug application (IND) for AURORAS-1 was cleared by the US Food and Drug Administration (FDA) in May 2025. ERAS-0015, which we license from Guangzhou Joyo Pharmatech Co., Ltd. (Joyo), is also being evaluated in the JYP0015M101 clinical trial in China, which is assessing ERAS-0015 in adult patients with advanced solid tumors harboring specific RAS mutations. The JYP0015M101 clinical trial is sponsored b … e early development of MEKINIST, and supported the successful biologics license application for IMFINZI in bladder cancer. 6   Dr. David Chacko, our Chief Financial Officer and Chief Business Officer, joined us from Versant Ventures, where he was a Principal with both investing and operating responsibilities. He helped lead investment opportunities across multiple therapeutic areas and advanced several Versant portfolio companies operationally through company formation, … Amsterdam and obtained his Ph.D. from Leiden University. After a post-doctoral fellowship, he became an assistant professor at Harvard University. In 1992, he joined the Netherlands Cancer Institute, where he continues to work at present. • Dr. Stephen Blacklow is a world expert in SHP2 who helped pioneer development of the first SHP2 inhi
EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1   Erasca Reports First Quarter 2026 Business Updates and Financial Results   Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 milli … nts, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028 SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2026. “We continu … , 2025. Erasca expects its cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. Research and Development (R&D) Expenses: R&D expenses were $27.3 million for the quarter ended March 31, 2026, compared to $26.0 million for the quarter ended March 31, 2025. The increase was primarily driven by increases in personnel costs, including stock-based compensation expense, and expenses incurred in connection with clinical trials, pr … and the sufficiency of our cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. Actual results may differ from those set forth in this press release due to the risks and uncertainties   inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; the timing of our cl … patents held by RevMed or was derived from RevMed trade secrets; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the h
News Briefs | Virginia Wesleyan University We are performing scheduled system maintenance this evening. Some features may be temporarily unavailable. --> Accessibility Menu Skip to Main Content Accessibility Menu Skip to Main Content Become a Marlin Scholarship Calculator Inquire Visit Apply Scholarship Calculator Inquire Visit Apply Give Menu Search Main Site Navigation Scholarship Calculator Inquire Visit Apply Give --> Search our site Submit Search About About VWU Home About Us Our Mission Our History Our Heritage and Values Accreditation Accolades Traditions Campus Information Campus Map C … hip Registrar Security Transcripts University Store Site Search Search our site Submit Search Popular Searches Commencement Academic Calendar Campus Map Catalog Employment Learning Center (advising/tutoring) Library Majors Registrar Tuition University Store (books/merchandise) Scholarship Calculator Info Visit Apply News Briefs Home About News and Events News Briefs Toggle Section Menu News & Events Menu About VWU News & Events Features & News Features News Campus … enu About VWU News & Events Features & News Features News Campus Events Submit an Event The Wesleyan Review VWU Magazine VWU Digital Broadcasting Network Tradition Transformed Podcast Campus Snapshots VWU on Flickr Marketing and Communications Close Menu Close Menu 2026 Spring 2026 President's List and Dean's List Announced (06-08-2026) Congratulations to the 156 students on the President’s List who achieved a 4.0 grade point average for spring 2026, and to the … evening’s highlights was the presentation of the 2026 Norfolk Sports Club Award to Laci Campbell. This prestigious honor recognizes Canpbell’s outstanding performance throughout her collegiate career at VWU, not only as an accomplished softball player, but also as a respected leader among her peers. Sarah Guzzo, Director of Stewardship, was also recognized at the event as the recipient of the Lawrence D. Hultgren Friend of Athletics Award, presented by Dire … etic fundraising efforts, including leadership support for the Marlin Athletics Fund, and this honor reflects her outstanding commitment to student-athletes. Congratulations to all student-athletes! Seven Students Inducted into Iota, Iota, Iota, the National Honor Society for Women's and Gender Studies (05-06-2026) On Apr
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
EX-99.1 2 eras-ex99_1.htm EX-99.1 EX-99.1 Erasca Reports Second Quarter 2023 Financial Results and Business Updates   Significant progress across all clinical programs including Phase 1b combo data for ERAS-007 and ERAS-601, FTD and ODD granted for ERAS-801, and publication of naporafenib combination data Multiple meaningful clinical catalysts over the next 18 months and beyond Strong balance sheet with cash, cash equivalents, and marketable securities of $365 million as of June 30, 2023, expected to fund operations into H2 2025 SAN DIEGO, August 10, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. … xpects its current cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2025. Research and Development (R&D) Expenses: R&D expenses were $26.2 million for the quarter ended June 30, 2023, compared to $27.5 million for the quarter ended June 30, 2022. The decrease was primarily driven by decreases in expenses incurred in connection with clinical trials, preclinical studies, discovery activities and outsourced services and … ctation that our current cash, cash equivalents, and marketable securities will fund our operations into the second half of 2025. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: preliminary results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, follo … enses; the impact of global geopolitical events on our business; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ending December 31, 2022, and any subsequent filings with the SEC. You are cautioned not to place undue r
Erasca Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Compet … ctation that our current cash, cash equivalents, and marketable securities will fund our operations into the first half of 2026. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; potential delays in the … he impact of global geopolitical events and war on our business; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2022, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on thes
PRX Piece: An Interview with Jonathan E. Lim, MD, Co-founder of IGNYTA Playing An Interview with Jonathan E. Lim, MD, Co-founder ... From Peter Hofland Track Buffer Seek Playhead Previous Play Pause Next Mute Unmute Volume selector Volume level indicator For this edition of The OncoZine Brief, we sat down with Jonathan E. Lim , M.D. co - founder of IGNYTA , and its President and Chief Executive Officer since July 2012. Lim is the Founder and Managing Partner at City Hill Ventures, a company he founded in 2010. He is also a Co - Founder &nbs … 03 to 2010. Lim was a recipient of a National Institutes of Health Postdoctoral Fellowship, during which time he conducted clinical outcomes research at Harvard Medical School. His prior experience also includes two years of clinical training/ residency in general surgery at the New York Hospital-Cornell Medical Center and Memorial Sloan-Kettering Cancer Center; Founding Editor-in-Chief of the McGill Journal of Medicine; and basic science and clinical research at the Salk Ins
EX-10.1 2 eras-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1   CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED LICENSE AGREEMENT This License Agreement (this “ Agreement ”) is made as of May 15, 2024 (the “ Effective Date ”), by and between Guangzhou Joyo Pharmatech Co., Ltd. (in Chinese, 广州嘉越医药科技有限公司) , a corporation duly organized and existi … cal products in the Erasca Territory (as defined below), and Joyo is willing to grant such a license to Erasca, all in accordance with the terms and conditions set forth herein. Agreement Now, Therefore , in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows: Article 1 DEFINITIONS The terms in this Agreement with initial letters capitalized shall h … ” means any compound that: (a) (i) is disclosed in the following patent application: [***] or (ii) is owned or otherwise controlled by Joyo or its Affiliate as of the Effective Date and whose mechanism of action is Pan-RAS Inhibition, including [***], or 3     (b) is a derivative, modification or improvement of any compound described in the foregoing clause (a) that is created, discovered, developed or generated by or on behalf of a Party or its Affiliates o … nts or other Intellectual Property Rights and, in each case, has the ability to grant to the other Party access, a license, or a sublicense (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or other legally enforceable arrangement with any Third Party. Notwithstanding anything in this Agreement to the contrary, (a) a Party will be deemed to not Control any Know-How, Patents or ot … sequently acquired or licensed by such Third Party, and (b) in the event that a grant by a Party to the other Party of a license, access, or other right in, to, or under, any Know-How, Patents or other Intellectual Property Rights requires payment to a Third Party or compliance with obligations required to be passed onto a sublicensee of such Kno
From Surgeon to Biotech CEO wi… - Raising Health - Apple Podcasts Search Home New Top Charts Search October 15, 2024 28 min From Surgeon to Biotech CEO with Jonathan Lim Raising Health Play Jonathan Lim is the CEO of Erasca, but his career path took him on a fascinating journey from practicing as a surgeon to leading life science companies. In a recent conversation, Lim shared valuable insights about his transition to the biotech world, his leadership experiences, and the lessons he's learned while founding and guiding organizations through high-stakes decision making. Reflecting on a pe
Erasca Reports Third Quarter 2025 Business Updates and Financial Results | Technology Review Djibouti Searching… AGP Picks How Iran Devastated an American Naval Base Putin’s Reign may not Survive the Impending Fall of Crimea France, Spain and Italy Impose a Digital Services tax of 3% on Large Companies Working in Their Countries How Leftist Zines Were Used to Convict a Group of Protesters Accused of Ties to Antifa Meta Lobbies for Exemption From Child-Harm Penalties Billionaire Wealth Tax Headed to the California Ballot Scratching That bug Bite Might Feel Good at First but Science Explains why … curities of $362 million as of September 30, 2025 is expected to fund operations into H2 2028 SAN DIEGO, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended September 30, 2025. “Our R … a expects its cash, cash equivalents, and marketable securities balance to fund operations into the second half of 2028. Research and Development (R&D) Expenses:  R&D expenses were $22.5 million for the quarter ended September 30, 2025, compared to $27.6 million for the quarter ended September 30, 2024. The decrease was primarily driven by decreases in expenses incurred in connection with clinical trials, preclinical studies, di … and the sufficiency of our cash, cash equivalents, and marketable securities to fund operations into the second half of 2028. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; results from preclinical st … es and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; we may use our capital resources sooner than we expect; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the h
StockWatch:... - Genetic Engineering & Biotechnology News Facebook Log In Genetic Engineering & Biotechnology News's Post Genetic Engineering & Biotechnology News May 4 · Shared with Public StockWatch: Patient Death, Rival's Patent Challenge Sink Erasca Shares Investor selloff follows 66-year-old man succumbing to pneumonitis and Revolution Medicine's claim that ERAS-0015 is equivalent to daraxonrasib; Erasca CEO Jonathan E. Lim, MD, tells GEN company plans vigorous defense, cites preliminary positive early clinical data. Plus, Alex Philippidis covers more leaders an
MD Anderson and Erasca announce collaboration on RAS/MAPK-driven cancers | UT MD Anderson Skip to Content My Chart Log in to our secure, personalized website to manage your care (formerly myMDAnderson). Request an Appointment Request an Appointment If you are ready to make an appointment, select a button on the right. If you have questions about UT MD Anderson’s appointment process, our information page may be the best place to start. Appointment Information New Patients Current Patients Referring Physicians Donate Today Search Close Menu Close Clinical Trials Locations Careers Contact Us Our … e Donate Home Raise Money Honor Loved Ones Create Your Legacy Endowments Caring Fund Matching Gifts Foundation and Corporation Relations Volunteer Volunteer Volunteer Home Why Volunteer On-Site Volunteers Volunteer Endowment Patient Experience Teen Volunteer Leadership Program Children's Cancer Hospital Councils Other Ways to Help Other Ways to Help Other Ways to Help Home Give Blood Shop UT MD Anderson Children's Art Project Donate Goods or Services Attend Events Cor … r Programs Comparative Effectiveness Training (CERTaIN) Faculty Speakers Bureau Apply to SHP Choose from 12 allied health programs at School of Health Professions. Research Trainees View open postdoctoral and other research trainee positions. GME Fellowships Learn about our graduate medical education residency and fellowship opportunities. UT MD Anderson Newsroom 2022 08 MD Anderson and Erasca announce strategic research and development collaboration in RAS/MAPK-driven cancer
StockWatch: Patient Death, Rival's Patent Challenge Sink Erasca Shares genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsle … U.K.’s Medicines and Healthcare Products Regulatory Agency (MHRA) and plans to submit a Marketing Authorization Application (MAA) for AMT-130 for the treatment of Huntington’s disease in the third quarter. The company said it expects to submit an MAA based on a three-year analysis from its ongoing U.S. and European Phase I/II clinical trials. GEN Edge Industry News News Cancers Colorectal cancer Medicine, Diagnosis, and Therapeutics Non-small cell lung cancer Pancreatic canc
Biotech Erasca taps MD Anderson to help advance cancer drug work | BioPharma Dive Skip to main content CONTINUE TO SITE ➞ Don't miss tomorrow's biopharma industry news Let BioPharma Dive's free newsletter keep you informed, straight from your inbox. Daily Dive M-F Commercialization Weekly Every Wednesday Gene Therapy Weekly Every Thursday Emerging Biotech Weekly Every Tuesday By signing up to receive our newsletter, you agree to our Terms of Use and Privacy Policy . You can unsubscribe at anytime. Informa TechTarget | Healthcare Dive MedTech Dive PharmaVoice Xtelligent Pharma Life Sciences Exp
Member Spotlight: Erasca - Biocom Skip to main content Search Cancel Select Location Choose a location San Diego Greater Los Angeles Bay Area Seattle Sacramento Washington, D.C. Tokyo Enter your location ZIP Code Submit Location Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podcast Episodes About About Us Our Team Board of Directors Careers Contact Our Locations San Dieg … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Membership Member Benefits Become a Member Conference & Events Funding & Partnering Group Purchasing Policy & Advocacy Workforce Development International Connections Increase Visibility Community Building Catalyst: Innovators Under 40 CEO/Founder Network Converge … ent Member Benefits Career Hub HR Biotech Group (HRBG) Professional Development Fellowship Programs Affiliated Organizations Biocom Institute Generation STEAM Festival of Science & Engineering Join Member Login Career Hub Venture Hub News & Insights Newsroom News Releases Media Resources In the News Economic Impact Report CEO Updates Newsletters Subscribe Regional Policy & Advocacy Group Purchasing LifeLines Innovations Interviews Insights Involvement Past Podc … to do something I had never done before, I learned a great deal and was able to apply cross-disciplinary learnings to each new experience, helping me to become a more effective leader. That said, it’s still an ongoing journey and I still have much to learn. This month is Asian American and Pacific Islander Heritage Month. What does AAPI Heritage Month mean to you, and why is it important that everyone celebrates it? I am incredibly proud of my own heritage, but I will say tha
A Look at Fast Growing Managers in OWL Home Posts A Look at Fast Growing Managers in OWL A Look at Fast Growing Managers in OWL New Form ADV filings show who grew the most over the past year Apr 14, 2026 Early April is an exciting time at OWL with an influx of new ADVs, which most managers file by 3/31 for the prior fiscal year. This week, our team sifted through the data to find some interesting trends on which firms are growing (or shrinking) the most. The table below shows the AUM changes of our “OWL Groups” – curated lists of over 500 managers frequently found in leading allocators’ portfo … ing manager is Paradigm Biocapital, a healthcare and therapeutics-focused hedge fund based in New York City. The manager’s regulatory AUM has grown rapidly since its founding in 2020, starting with $129 million after its first year and reaching $4.5 billion as of its latest Form ADV in March of this year. Paradigm’s funds have raised approximately $1.5 billion since inception, accounting for just over one-third of its total AUM. Founded by Senai Asefaw , a former director at … is keeping all but a few firms away. King Street and PIF Partner on MENA Credit Fund This hedge fund launched with billions, then cruised under the radar. It has quietly doubled in size (Freestone Grove) A New Short-Only Fund Is Coming — And Markets May Be Ready for It Tiger Cubs Viking, Maverick Pummeled Last Month Amid War in Iran The new investing edge might be hiding in firms' own data Podcast With Bruce MacDonald (VCUIMC) He Turned Down Ken Griffin to Run His Own Fu … d family offices use the system to find, monitor, and connect with thousands of fund managers globally. OWL's analytics engine has collected over one billion data points from 65 countries. We make it easy for allocators to find and track information about the managers they care about – not just positions but also performance analytics, people data, business information, and details about the manager investments of other allocators. Reach out for a demo! Disclaimers Retur … siness relationships with such parties. Accordingly, references to any manager, fund, or LP should not be construed as an endorsement, recommendation, or solicitation. Old Well Labs shall not be liable for any investment gain or loss that may occur from the use of this material. No part of this material may be reproduced in any form or used in an
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
About - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Competitive Benefits Open Positions Stay in Touch 858.465.6511 [email protected] about At erasc
Brian Cuneo - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact > Brian Cuneo Senior Partner Brian Cuneo is a Senior Partner with ARCH working on new company creation and advising on strategic portfolio matters. He was previously a partner of Latham & Watkins LLP, serving as Global Chair of the firm’s Life Sciences and Healthcare Industry Group. Mr. Cuneo has spent his career advising public and private companies in the biotechnology, medical
ISPOR - Welcome and Keynote Address - Winning the Next Biotech Cycle: What Winners Must Get Right Toggle navigation About Get Involved Membership Manage Profile Logout Join/Renew Toggle navigation HEOR Resources HEOR Explained HEOR Explained is an accessible way to understand what HEOR is, how it’s used, and its impact on people and healthcare systems. A resource for all, created by ISPOR. HEOR Explained Top 10 HEOR Trends HEOR by Topic Clinical Outcomes Digital Health, Devices, and Diagnostics Economic Evaluation Epidemiology Healthcare Delivery Health Policy Health Technology Assessment … Consortia Networks Regional Chapters Join an ISPOR Global Member Group Students Apply For/Renew Membership Student Council Student Chapters Student Network Committees Faculty Advisor Council Webinars Student Newsletters New Professionals Professional Development Resources Online Communities Home HEOR Resources ISPOR Presentations Database Session (CTI) Welcome and Keynote Address - Winning the Next Biotech Cycle: What Winners Must Get Right Speaker George Scangos, PhD, A
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Videos Mult … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
Episode 32: ARCH Venture Partners' Bob Nelsen - BioVenture VoiCes with Chris Garabedian | Podcast on Spotify
Bob Nelsen on Arch Venture Partners' Risk-Taking Approach | Chris Garabedian posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in
Team - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact Our Team We are contrarian. We are bold. We are imaginative risk takers. Robert Nelsen Co-founder & Managing Director View Bio Keith Crandell Co-founder & Managing Director View Bio Kristina Burow Managing Director View Bio Steve Gillis, Ph.D. Managing Director View Bio Paul Berns Managing Director View Bio Clinton Bybee Co-founder & Managing Director, Emeritus View Bio Mark McDonnell Manag
Best Biotech Keynote Speaker for ARCH Venture Portfolio Biotech Companies | Dr. Noah St. John | Neural Performance Architect Dr. Noah St. John Neural Performance Architect Home Hire Noah Speaking Check Availability Dr. Noah St. John | Neural Performance Architect | Worldwide Best Biotech Keynote Speaker for ARCH Venture Portfolio Biotech Companies Dr. Noah St. John is known worldwide as The Neural Performance Architect. If you lead ARCH venture portfolio biotech companies and you are searching for best biotech keynote speaker, the strategy is not the problem. The Invisible Brake™ is. Check Noa
ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner - ARCH Venture Partners You are using an outdated browser. Please upgrade your browser to improve your experience. Toggle navigation About Portfolio Initiatives Strategic Partnerships Team News Contact ALL NEWS ARCH Venture Partners Announces Appointment of Brian Cuneo as Senior Partner April 6, 2023 Press Releases from ARCH Venture Partners | Share CHICAGO – ARCH Venture Partners, one of the world’s leading early-stage technology venture firms, today announced the appointment of life sciences industry v
All eyes on Revolution, bispecific antibodies and more at ASCO26 - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Drug Development All eyes on Revolution, bispecific antibodies and more at ASCO26 May 26, 2026 | 6 min read | Brianna Abbott Twitter LinkedIn Facebook Email Print iStock, Iryna Olkhova Partners Summit Therapeutics and Akeso are expected to steal the show at the American Society of Clinica … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Erasca (NASDAQ: ERAS) climbs into ASCO 2026 as pan-RAS thesis gets second wind | Business News Today Reporter LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in,
Erasca Announces Three Presentations at the 2024 ASCO Annual Meeting - Erasca About People Science Pipeline Patients Investors Careers Overview Vision & Values Founder’s Letter Contact Overview Leadership Team Board of Directors Scientific Advisory Board Research, Development, and Commercial Advisory Board RAS/MAPK Pathway MAPKlamp & More Presentations & Publications Pipeline Programs Clinical Trials Patients & Caregivers Clinical Trials Corporate Overview News & Events Stock Information Financial Information Investor Resources Dynamic Culture Values & Attributes Competitive Benefits Open Posi … ood that our product candidates will receive marketing approval; our ability to fund our operating plans with our current cash, cash equivalents, and marketable securities; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2023, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on thes
ERAS – Erasca, Inc. 13F Top Holders Q2 2023 vs. Q3 2023 Erasca, Inc. Q2 2023 vs. Q3 2023 13F Holders Period Q2 2023 Q3 2023 Num holders 115 114 Total reported value, excl. options $205 M $140 M Total shares, excl. options 74,333,173 71,305,182 Compare Q3 2023 to 2026 Q1 2025 Q4 2025 Q3 2025 Q2 2025 Q1 2024 Q4 2024 Q3 2024 Q2 2024 Q1 2023 Q4 2023 Q2 2023 Q1 2022 Q4 2022 Q3 2022 Q2 2022 Q1 2021 Q4 2021 Q3 Manager Q2 2023 Shares Q3 2023 Shares Diff Chg % All Managers A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0 Latest Filings Privacy Policy
Symbol,Description,Total Shares,Total Trades,Last Update AAIC,ARLINGTON ASSET CL A,200,2,2021-10-16 AAN,AARONS CO THE,100,1,2021-10-16 AAON,AAON INC,35,2,2021-10-16 AAT,AMERICAN ASSETS TRST,436,10,2021-10-16 AAWW,ATLAS AIR WW,640,13,2021-10-16 AB,ALLIANCEBERNSTEIN,420,6,2021-10-16 ABB,ABB LTD,7191,117,2021-10-16 ABCB,AMERIS BANCORP,308,12,2021-10-16 ABCL,ABCELLERA BIOLOGICS,1946,30,2021-10-16 ABEO,ABEONA THERAPEUTICS,100,1,2021-10-16 ABEV,AMBEV SA,421219,2126,2021-10-16 ABG,ASBURY AUTOMOTIVE GR,24,6,2021-10-16 ABM,A B M INDUSTRIES INC,69,8,2021-10-16 ABNB,AIRBNB INC CL A CMN,7397,125,2021-10-1 … 16 REZI,RESIDEO TECH,2480,30,2021-10-16 RFL,RAFAEL HLDGS INC,2270,34,2021-10-16 RFP,RESOLUTE FOREST PDS,2669,39,2021-10-16 RGNX,REGENXBIO INC CM,273,47,2021-10-16 RGS,REGIS CP,20043,147,2021-10-16 RHP,RYMAN HOSPITALITY PP,335,8,2021-10-16 RIDE,LORDSTOWN MOTORS,43939,260,2021-10-16 RIG,TRANSOCEAN LTD,352187,1444,2021-10-16 RIGL,RIGEL PHARMACEUTICAL,6660,49,2021-10-16 RILY,B RILEY FINANCL CMN,41,2,2021-10-16 RIO,RIO TINTO PLC ADS,9030,275,2021-10-16 RIOT,RIOT BLOCKCHAIN INC,108
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
ERAS Insider Buying — Recent SEC Form 4 Activity (2026) | InsiderAct | InsiderAct Insider Act Home Signals Insiders Transactions Watchlist Learn Subscribe Home / Stocks / ERAS ERAS Insider Buying — Recent SEC Form 4 Activity Track insider buying activity for Erasca, Inc. ( $ ERAS ). See every SEC Form 4 purchase by CEOs, CFOs, directors, and 10% owners over the last 90 days — sourced directly from EDGAR. No insider purchases recorded for Erasca, Inc. (ERAS) in the past 90 days. Purchases (90d) 0 Total value — Unique insiders 0 See full $ ERAS insider activity → Recent Insider Purchases at Eras
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Immunovant Inc (IMVT-Q) Stock Price and News - The Globe and Mail Home Canada Business Investing Life Opinion World Politics Personal Finance Culture Sports More More Latest in More Real Estate Drive Watchlist For You Events Find clarity in the chaos. Subscribe now and save 70% Subscribe Digital access Digital + home delivery TSX 0.37 % S&P 500 -0.05 % DOW -0.09 % NASDAQ -0.24 % Oil -3.74 % Dollar 0.05 % Gold 1.2 % tsx movers: CNQ-T -0.3 % BB-T + 10.33 % SU-T -0.87 % TRP-T -0.77 % Instrument Name Immunovant Inc Instrument Symbol (IMVT-Q) Instrument Exchange NASDAQ Add to Watchlist Create A … te and/or trade prices are not sourced from all markets. Select a category then submit the form to load news All news The Globe and Mail Analysis Press releases Tipranks Analysts Are Bullish on Top Healthcare Stocks: Allogene Therapeutics (ALLO), Immunovant (IMVT) May 30, 2026 Tipranks Analysts’ Top Healthcare Picks: Amneal Pharmaceuticals (AMRX), Immunovant (IMVT) May 27, 2026 Tipranks H.C. Wainwright Reaffirms Their Buy Rating on Immunovant (IMVT) May 27, 2026 Tipranks Anal … Erasca (ERAS) May 26, 2026 Motley Fool This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million May 24, 2026 Motley Fool This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter May 24, 2026 Motley Fool What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge May 23, 2026 Motley Fool Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally May 23, 2026 Tipranks Immunovant’s Ta … rth Quarter and Fiscal Year Ended March 31, 2026 May 20, 2026 Motley Fool Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval May 18, 2026 Motley Fool Hedge Fund Drops $40 Million on Gene-Editing Biotech Beam. Is It a Buy? May 18, 2026 Motley Fool Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? May 18, 2026 GlobeNewswire Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Pro … nstitute Contact us Address and Phone Number Standards Editors Staff SecureDrop Submit an article Reader services Account Settings Customer Support Subscriptions Member Benefits Privacy Settings About us Company information Work at The Globe Accessibility Editorial Code of Conduct Sustainability Licensing & Permissions Election Advertising Re
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia
Speaker Biographies Conference Agenda Attendees Speaker Biographies Partnering Partnering Platform Who Should Attend Sponsorship Sponsorship Opportunities Sponsorship Prospectus Media Press Registration Media Partners Register Individual Pricing Group Pricing Warning! Web API Url is not set for the Speaker Bios. Speaker Biographies Filter by: Last Name Organization Program Clear Filters ‹ › × Steve Ardire, Independent AI Startup Advisor Independent Advisor Independent AI Startup Advisor Steve is AI startup ‘force multiplier' / Quintessential 'Merchant of Light'. He built a … tor Institute. Amongst other awards, Alán is a recipient of the Google Focused Award in Quantum Computing, the MIT Technology Review 35 under 35, and the Sloan and Camille and Henry Dreyfus Fellowships. Alán is a fellow of the American Association of the Advancement of Science and the American Physical Society. He is a co-founder of Zapata Computing and Kebotix, two early-stage ventures in quantum computing and self-driving laboratories respectively. DECODE: AI for Pharmace … the Broad in 2019 to tackle the next great data problem of our time: how do we apply machine learning on the vast rams of clinical and genomic data to drive breakthroughs in how we prevent, diagnose, and treat disease? Batra completed his B.A. in physics at Harvard University and has a Ph.D. in theoretical physics from Stanford University. DECODE: AI for Pharmaceuticals Paul A. Bleicher, PhD, Principal, Evident Health Strategies Principal Evident Health Strategies As Princip … town University School of Medicine for his M.D. He then completed his pediatric residency at Children’s Hospital National Medical Center and his pediatric cardiology fellowship at the Children’s Hospital of Philadelphia. He then accepted a position as attending cardiologist in the cardiovascular intensive care unit of Boston Children’s Hospital and as assistant professor at Harvard Medical School. He has been the medical director of several pediatric cardiac intensive c … tion at the University of Miami School of Business and graduated with the McCaw Award of Academic Excellence. He also completed a Masters in Public Health (MPH) in Health Care Policy at the Jonathan Fielding School of Public Health of the University of California, Los Angeles and graduated with the Dean’s Award for Academic Excellence. He later
Submit to Current Drug Targets: A Bentham Science Journal | Current Drug Targets posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in … o main content LinkedIn Top Content People Learning Jobs Games Join now Sign in Submit to Current Drug Targets: A Bentham Science Journal Current Drug Targets 193 followers 5mo Edited Report this post Current Drug Targets —an international, peer-reviewed journal by Bentham Science , invites researchers and pharmaceutical scientists to submit full-length reviews, mini-reviews, drug clinical trial studies, and guest-edited thematic issues focusing on molecular drug targets. 🔗 … , Ph.D., Pharm.D. , Commercialized ADCs: A Market Snapshot for Exemplification; Application of #ADCs to #Therapeutic Areas Outside of #Oncology - Anna Papinska , Mitalee Tamhane , Mihir Shah ; #Regulatory Framework for the #Manufacturing and #Marketing of #ADCs - Hriday Gondalia ; #Conjugation #Chemistry and #Chemical Design for the #Discovery and #Development of #Antibody #Drug #Conjugates - Amir Assadieskandar, Golnaz Kamalinia; #Clinical #Pharmacology Considerations in #An … .S. Food and Drug Administration ( FDA ) for its Investigational New Drug (IND) application for LGW16-03. Read more: https://lnkd.in/gE26XcB4 #TraceBiosciences #SurgicalInnovation #NerveTrace #MedTech #PatientSafety #PrecisionSurgery #FDAApproval #HealthTech #SurgeonLife #Innovation #PharmaIndustrialIndia Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in 193 followers View Profile Follow Explore content categories Career Productivity Finance Soft S
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
--> Erasca Added to the Nasdaq Biotechnology Index --> Login Start Free Trial Catalyst Calendar FDA Calendar Track key readouts and FDA decision dates in biotech and pharma. BPW Portfolio Bio Hedge Fund Shots and more... Historical FDA Calendar Review past FDA decisions and clinical readouts. Market Movers Track today's biotech market movers Biotech Earning Calendar Stay updated on biotech earnings. Historical PDUFA Dates Review past PDUFA dates and decisions. PDUFA Calendar Stay ahead of upcoming PDUFA dates Conference Calendar Keep up with biotech events. IPO Upcoming & past IPOs. Bio Ph … p; past IPOs. Bio Pharma Screener Catalyst Sync™ Track biotech catalysts. Hedge Fund Screener Analyze hedge fund holdings. Company Screener Holistic company & pipeline analysis. All Stocks Holdings Explore hedge fund stock data. Heat-Map Market size & sector heat map. Inside Trades Monitor insider trading. Biotech Analyst Ratings Biotech analyst ratings & price targets M&A Tracker Track M&A deals and acquisition targets Resources News Latest biotech news.
Tietosuojavalintasi guce guce Tietosuojasi on meille tärkeää Tietosuojavalintojasi käytetään kaikissa Yahoo-konsernin tarjoamissa sivustoissa ja sovelluksissa. Yahoo käyttää evästekäytännöstämme ."> Evästeet Evästeiden (sekä vastaavien tekniikoiden, esimerkiksi verkkotallennuksen) avulla verkkosivustojen sovellusten ylläpitäjät voivat tallentaa ja lukea laitteesi tietoja. Lue lisää evästekäytännöstämme . evästeitä seuraaviin tarkoituksiin: tarjotaksemme sivustomme ja sovelluksemme sinulle todentaaksemme käyttäjät, estääksemme roskapostia ja väärinkäytöksiä sekä toteuttaaksemme tietoturvatoimia